-- Achieved all co-primary endpoints of LS mean reduction in LDL-C on top of maximally tolerated lipid-modifying therapies versus each…
CHICAGO, Nov. 16, 2024 (GLOBE NEWSWIRE) -- In August of 2023, the Foundation for Sarcoidosis Research (FSR) submitted a Request…
Consistently rapid, deep and durable reduction in serum TTR accompanied by evidence of disease stabilization or improvement after a one-time…
CHICAGO, Nov. 16, 2024 (GLOBE NEWSWIRE) -- In August of 2023, the Foundation for Sarcoidosis Research (FSR) submitted a Request…
Consistently rapid, deep and durable reduction in serum TTR accompanied by evidence of disease stabilization or improvement after a one-time…
November 09, 2024 13:00 ET | Source: Replimune Group Inc Oral presentation highlighting IGNYTE primary analysis data shows anti-tumor activity…
New data showed a correlation between the levels of neural cell adhesion molecule (NCAM or CD56) expression and response and…
November 01, 2024 17:30 ET | Source: OnKure Therapeutics, Inc. OnKure to host a conference call to review key data…